Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$39.19 USD
+0.73 (1.90%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $39.21 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$39.19 USD
+0.73 (1.90%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $39.21 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU
by Zacks Equity Research
Conatus (CNAT) secures orphan drug designation for its pipeline candidate, IDN-7314, granted by the EMA. The candidate currently undergoes a phase II study on curing primary sclerosing cholangitis.
Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) will independently develop Inotersen and IONIS-FB-L Rx as GlaxoSmithKline declines its option on both drugs.
Ionis Pharmaceuticals (IONS) Misses on Q2 Earnings
by Zacks Equity Research
Ionis Pharmaceuticals' (IONS) reported loss of 9 cents including stock based compensation was wider than expectation. However, sales beat estimates.
Why Earnings Season Could Be Great for Ionis (IONS)
by Zacks Equity Research
Ionis (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) received marketing approval in the EU for spinal muscular atrophy and its launch is expected to further grow sales in Q2.
Ironwood (IRWD) Reports Positive Data on Reflux Candidate
by Zacks Equity Research
Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease.
Why is Alnylam's (ALNY) Stock Close to 100% this Year?
by Zacks Equity Research
Shares of Alnylam Pharmaceuticals, Inc. (ALNY) soared 93.3% this year so far massively outperforming the 2.6% increase registered by the Zacks classified Biomed/Genetics industry during this period.
Biogen/Ionis Spinraza Granted Marketing Authorization in EU
by Zacks Equity Research
Biogen Inc. (BIIB) announced granting of marketing authorization to its marketed drug Spinraza (nusinersen) by European Commission under the accelerated assessment program for treating patients with 5q spinal muscular atrophy.
Biogen's Fampyra Conditional Approval Converted to Standard
by Zacks Equity Research
Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.
Ionis (IONS) Stock Falls Despite Positive Inotersen Data
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) announced that the phase III study NEURO-TTR on inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints.
Biogen (BIIB) Buys Stroke Candidate Cirara for $120M
by Zacks Equity Research
Biogen Inc. (BIIB) announced the acquisition of Remedy Pharmaceuticals' phase III candidate, Cirara for the treatment of large hemispheric stroke (LHI).
Here's Why Shares of Ionis Pharma (IONS) are Falling Today
by Madeleine Johnson
On Monday, shares of Ionis Pharmaceuticals Inc. (IONS) are falling, down about 10% in morning trading after the company announced results from its 15-month long Phase 3 Neuro-TTR Study of its drug Inotersen (IONIS-TTRrx).
Ionis Pharmaceuticals (IONS) Beats on Q1 Earnings
by Indrajit Bandyopadhyay
Ionis reported earnings of 3 cents including stock based compensation which surpassed the Zacks Consensus Estimate of loss of 4 cents
4 Drug Stocks Poised to Beat this Earnings Season
by Zacks Equity Research
M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017.
What's in Store for Immune Design (IMDZ) Stock in Q1 Earnings?
by Zacks Equity Research
Immune Design Corp (IMDZ) is expected to report first-quarter 2017 results on May 9.
Teva Pharmaceutical (TEVA) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to report first-quarter 2017 earnings on May 11
Why Ionis (IONS) Might Surprise This Earnings Season
by Zacks Equity Research
Ionis (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in the Cards for Ionis (IONS) this Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report first-quarter 2017 results on May 9. Last quarter, the company recorded a positive earnings surprise of 265%. Let's see how things are shaping up for this announcement.
Ionis Pharma Lipid Disorder Candidate Positive in Phase III
by Zacks Equity Research
Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. (IONS), recently announced positive results from a pivotal phase III study evaluating its pipeline candidate volanesorsen for treatment of patients with familial chylomicronemia syndrome.
Ionis Pharmaceuticals (IONS) Beats on Q4 Earnings
by Zacks Equity Research
Ionis reported earnings of 21 cents including stock based compensation. However, excluding stock based compensation the company reported earnings of 33 cents that surpassed the Zacks Consensus Estimate of loss of 20 cents.
Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.
Ionis Pharmaceuticals (IONS) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) has been struggling lately, but the selling pressure may be coming to an end soon
Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017
by Zacks Equity Research
We issued an updated research report on Biogen Inc. (BIIB) on Jan 16.
Biogen (BIIB) Presents Positive Phase III Data on Spinraza
by Zacks Equity Research
Biogen Inc. (BIIB) presented positive data from the phase III ENDEAR study evaluating Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).
Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments
by Zacks Equity Research
Ionis (IONS) entered into a collaboration agreement with Novartis (NVS) for the development and commercialization of AKCEA-APO(a)-L and AKCEA-APOCIII-L.